193 related articles for article (PubMed ID: 36423362)
1. COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.
Pixberg C; Zapatka M; Hlevnjak M; Benedetto S; Suppelna JP; Heil J; Smetanay K; Michel L; Fremd C; Körber V; Rübsam M; Buschhorn L; Heublein S; Schäfgen B; Golatta M; Gomez C; von Au A; Wallwiener M; Wolf S; Dikow N; Schaaf C; Gutjahr E; Allgäuer M; Stenzinger A; Pfütze K; Kirsten R; Hübschmann D; Sinn HP; Jäger D; Trumpp A; Schlenk R; Höfer T; Thewes V; Schneeweiss A; Lichter P
ESMO Open; 2022 Dec; 7(6):100637. PubMed ID: 36423362
[TBL] [Abstract][Full Text] [Related]
2. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
3. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
[TBL] [Abstract][Full Text] [Related]
5. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Hlevnjak M; Schulze M; Elgaafary S; Fremd C; Michel L; Beck K; Pfütze K; Richter D; Wolf S; Horak P; Kreutzfeldt S; Pixberg C; Hutter B; Ishaque N; Hirsch S; Gieldon L; Stenzinger A; Springfeld C; Smetanay K; Seitz J; Mavratzas A; Brors B; Kirsten R; Schuetz F; Fröhling S; Sinn HP; Jäger D; Thewes V; Zapatka M; Lichter P; Schneeweiss A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036222
[TBL] [Abstract][Full Text] [Related]
6. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
8. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
10. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
11. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer.
Prakash I; Neely NB; Thomas SM; Sammons S; Blitzblau RC; DiLalla GA; Hyslop T; Menendez CS; Plichta JK; Rosenberger LH; Fayanju OM; Hwang ES; Greenup RA
Cancer Med; 2022 Feb; 11(4):1099-1108. PubMed ID: 34989142
[TBL] [Abstract][Full Text] [Related]
12. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
[TBL] [Abstract][Full Text] [Related]
13. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
15. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
18. Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in
Sokolenko AP; Moiseyenko FV; Iyevleva AG; Ivantsov AO; Dolmatov GD; Shelekhova KV; Gulo EV; Topal AX; Artemieva EV; Abduloeva NH; Rysev NA; Barsova DA; Levchenko NV; Volkov NM; Egorenkov VV; Moiseyenko VM; Imyanitov EN
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768191
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
Wang X; Fan Z; Wang X; He Y; Liu Y; Wang X; Zhang B; Jiang Z; Wang T; Yu Z; Wang F; Liu Y; Li Y; Zhang J; Luo B; Jiang H; Wang T; Xie Y; Li J; Ouyang T
Breast Cancer Res Treat; 2022 Oct; 195(3):301-310. PubMed ID: 35917052
[TBL] [Abstract][Full Text] [Related]
20. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE
Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
